IBDEI16I ; ; 20-MAY-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;OCT 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,21078,0)
 ;;=V10.52^^118^1265^9
 ;;^UTILITY(U,$J,358.3,21078,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,21078,1,1,0)
 ;;=1^V10.52
 ;;^UTILITY(U,$J,358.3,21078,1,8,0)
 ;;=8^Hx Of Kidney Malignancy
 ;;^UTILITY(U,$J,358.3,21078,2)
 ;;=^295229
 ;;^UTILITY(U,$J,358.3,21079,0)
 ;;=V10.46^^118^1265^29
 ;;^UTILITY(U,$J,358.3,21079,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,21079,1,1,0)
 ;;=1^V10.46
 ;;^UTILITY(U,$J,358.3,21079,1,8,0)
 ;;=8^Hx-Prostatic Malignancy
 ;;^UTILITY(U,$J,358.3,21079,2)
 ;;=^295224
 ;;^UTILITY(U,$J,358.3,21080,0)
 ;;=V10.47^^118^1265^32
 ;;^UTILITY(U,$J,358.3,21080,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,21080,1,1,0)
 ;;=1^V10.47
 ;;^UTILITY(U,$J,358.3,21080,1,8,0)
 ;;=8^Hx-Testicular Malignancy
 ;;^UTILITY(U,$J,358.3,21080,2)
 ;;=^295225
 ;;^UTILITY(U,$J,358.3,21081,0)
 ;;=V10.49^^118^1265^23
 ;;^UTILITY(U,$J,358.3,21081,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,21081,1,1,0)
 ;;=1^V10.49
 ;;^UTILITY(U,$J,358.3,21081,1,8,0)
 ;;=8^Hx-Male Genit Malig Nec
 ;;^UTILITY(U,$J,358.3,21081,2)
 ;;=^295226
 ;;^UTILITY(U,$J,358.3,21082,0)
 ;;=V10.45^^118^1265^24
 ;;^UTILITY(U,$J,358.3,21082,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,21082,1,1,0)
 ;;=1^V10.45
 ;;^UTILITY(U,$J,358.3,21082,1,8,0)
 ;;=8^Hx-Male Genit Malig Nos
 ;;^UTILITY(U,$J,358.3,21082,2)
 ;;=^295223
 ;;^UTILITY(U,$J,358.3,21083,0)
 ;;=V10.3^^118^1265^4
 ;;^UTILITY(U,$J,358.3,21083,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,21083,1,1,0)
 ;;=1^V10.3
 ;;^UTILITY(U,$J,358.3,21083,1,8,0)
 ;;=8^Hx Of Breast Malignancy
 ;;^UTILITY(U,$J,358.3,21083,2)
 ;;=^295217
 ;;^UTILITY(U,$J,358.3,21084,0)
 ;;=V10.41^^118^1265^15
 ;;^UTILITY(U,$J,358.3,21084,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,21084,1,1,0)
 ;;=1^V10.41
 ;;^UTILITY(U,$J,358.3,21084,1,8,0)
 ;;=8^Hx-Cervical Malignancy
 ;;^UTILITY(U,$J,358.3,21084,2)
 ;;=^295219
 ;;^UTILITY(U,$J,358.3,21085,0)
 ;;=V10.42^^118^1265^34
 ;;^UTILITY(U,$J,358.3,21085,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,21085,1,1,0)
 ;;=1^V10.42
 ;;^UTILITY(U,$J,358.3,21085,1,8,0)
 ;;=8^Hx-Uterus Malignancy Nec
 ;;^UTILITY(U,$J,358.3,21085,2)
 ;;=^295220
 ;;^UTILITY(U,$J,358.3,21086,0)
 ;;=V10.43^^118^1265^11
 ;;^UTILITY(U,$J,358.3,21086,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,21086,1,1,0)
 ;;=1^V10.43
 ;;^UTILITY(U,$J,358.3,21086,1,8,0)
 ;;=8^Hx Of Ovarian Malignancy
 ;;^UTILITY(U,$J,358.3,21086,2)
 ;;=^295221
 ;;^UTILITY(U,$J,358.3,21087,0)
 ;;=V10.44^^118^1265^18
 ;;^UTILITY(U,$J,358.3,21087,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,21087,1,1,0)
 ;;=1^V10.44
 ;;^UTILITY(U,$J,358.3,21087,1,8,0)
 ;;=8^Hx-Female Genit Malg Nec
 ;;^UTILITY(U,$J,358.3,21087,2)
 ;;=^295222
 ;;^UTILITY(U,$J,358.3,21088,0)
 ;;=V10.81^^118^1265^2
 ;;^UTILITY(U,$J,358.3,21088,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,21088,1,1,0)
 ;;=1^V10.81
 ;;^UTILITY(U,$J,358.3,21088,1,8,0)
 ;;=8^Hx Of Bone Malignancy
 ;;^UTILITY(U,$J,358.3,21088,2)
 ;;=^295239
 ;;^UTILITY(U,$J,358.3,21089,0)
 ;;=V10.82^^118^1265^25
 ;;^UTILITY(U,$J,358.3,21089,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,21089,1,1,0)
 ;;=1^V10.82
 ;;^UTILITY(U,$J,358.3,21089,1,8,0)
 ;;=8^Hx-Malig Skin Melanoma
 ;;^UTILITY(U,$J,358.3,21089,2)
 ;;=^295240
 ;;^UTILITY(U,$J,358.3,21090,0)
 ;;=V10.83^^118^1265^31
 ;;^UTILITY(U,$J,358.3,21090,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,21090,1,1,0)
 ;;=1^V10.83
 ;;^UTILITY(U,$J,358.3,21090,1,8,0)
 ;;=8^Hx-Skin Malignancy Nec
 ;;^UTILITY(U,$J,358.3,21090,2)
 ;;=^295241
 ;;^UTILITY(U,$J,358.3,21091,0)
 ;;=V10.84^^118^1265^6
 ;;^UTILITY(U,$J,358.3,21091,1,0)
 ;;=^358.31IA^8^2
